SPYRE THERAPEUTICS, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
SPYRE THERAPEUTICS, INC. (SYRE) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$14.50 million for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-08-09
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-06-30 was -$19.20M, a 524.40% decline year-over-year.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was $4.70M.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was $4.84M, a 89.29% increase year-over-year.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$6.29M.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$22.53M.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$12.08M.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$4.01M.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$221.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-06-30 | -$19.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$14.50M 10-Q · filed 2018-08-09 | -$9.65M derived: sum of 3 quarters · filed 2018-08-09 | -$15.94M derived: sum of 4 quarters · filed 2018-08-09 |
| 2018-03-31 | $4.70M 10-Q · filed 2018-05-08 | $9.55M derived: sum of 2 quarters · filed 2018-05-08 | $3.26M derived: sum of 3 quarters · filed 2018-05-08 | $7.78M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-12-31 | $4.84M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | -$1.44M derived: sum of 2 quarters · filed 2018-03-13 | $3.08M derived: sum of 3 quarters · filed 2018-08-09 | -$22.53M 10-K · filed 2018-03-13 |
| 2017-09-30 | -$6.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$1.76M derived: sum of 2 quarters · filed 2018-08-09 | -$27.37M 10-Q · filed 2017-11-07 | -$24.81M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-06-30 | $4.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$21.09M 10-Q · filed 2018-08-09 | -$18.53M derived: sum of 3 quarters · filed 2018-08-09 | -$33.82M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | -$25.61M 10-Q · filed 2018-05-08 | -$23.05M derived: sum of 2 quarters · filed 2018-05-08 | -$38.35M derived: sum of 3 quarters · filed 2018-05-08 | -$36.49M derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | $2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | -$12.74M derived: sum of 2 quarters · filed 2018-03-13 | -$10.88M derived: sum of 3 quarters · filed 2018-03-13 | -$12.08M 10-K · filed 2018-03-13 |
| 2016-09-30 | -$15.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$13.44M derived: sum of 2 quarters · filed 2017-11-07 | -$14.63M 10-Q · filed 2017-11-07 | -$15.14M derived: sum of 4 quarters · filed 2018-03-13 |
| 2016-06-30 | $1.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $660.00K 10-Q · filed 2017-08-09 | $150.00K derived: sum of 3 quarters · filed 2018-03-13 | -$3.31M derived: sum of 4 quarters · filed 2018-03-13 |
| 2016-03-31 | -$1.19M 10-Q · filed 2017-05-09 | -$1.70M derived: sum of 2 quarters · filed 2018-03-13 | -$5.16M derived: sum of 3 quarters · filed 2018-03-13 | -$5.19M derived: sum of 4 quarters · filed 2018-03-13 |
| 2015-12-31 | -$510.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | -$3.97M derived: sum of 2 quarters · filed 2018-03-13 | -$3.99M derived: sum of 3 quarters · filed 2018-03-13 | -$4.01M 10-K · filed 2018-03-13 |
| 2015-09-30 | -$3.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$3.48M derived: sum of 2 quarters · filed 2016-11-09 | -$3.50M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | -$24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$44.00K 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | -$20.00K 10-Q · filed 2016-05-19 | |||
| 2014-12-31 | -$221.00K 10-K · filed 2017-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |